RBC coverage restart puts Danaher (DHR) bioprocess outlook back in focus

RBC Capital’s decision to resume coverage of Danaher (DHR), pointing to an expected recovery in the bioprocess segment and easing prior headwinds, has pushed the stock back onto many investors’ watchlists.

At a share price of US$180.63, Danaher has seen a 4.3% 1 day share price return and a 4.2% 7 day share price return following RBC’s upbeat bioprocess commentary, although the year to date share price return is down 21.6% and the 1 year total shareholder return is down 4.5%. This points to improving short term momentum against a weaker multi year picture.

If this bioprocess recovery story has your attention, it can be useful to see what else is setting up for a rebound across healthcare and life sciences, starting with 35 healthcare AI stocks

With Danaher trading at US$180.63 alongside an estimated 20% intrinsic discount and a roughly 36% gap to analyst targets, you have to ask: is this a genuine entry point, or is the market already pricing in future growth?

Price to earnings of 34.8x: Is it justified?

Danaher trades on a P/E of 34.8x, which points to a premium price for its current earnings even though the stock is down 21.6% year to date.

The P/E multiple tells you how many dollars investors are currently paying for each dollar of earnings. For Danaher, that 34.8x figure suggests the market is willing to pay a relatively high price given the company’s earnings profile and exposure to biotechnology, life sciences, and diagnostics.

On one hand, Danaher screens as good value versus its peer group, with a P/E of 34.8x compared with a peer average of 38.8x. On the other hand, it stands slightly above the Global Life Sciences industry average of 34.6x and above an estimated fair P/E of 29.2x, which implies some compression in the multiple is a clear possibility if expectations cool.

Result: Price-to-earnings of 34.8x (ABOUT RIGHT)

However, there are still clear risks here, including a prolonged bioprocess slowdown and any reset to analyst expectations that narrows that 36% target gap.

Another view: what the SWS DCF model suggests

While the 34.8x P/E hints at a full price, our DCF model points in a different direction, with Danaher at $180.63 trading about 20% below an estimated fair value of $226.89. That gap frames the big question: is the cash flow story more important than the multiple?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Danaher for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the optimism in this article matches your own view on Danaher? Act while information is fresh and pressure test the upside by reviewing the 3 key rewards

Looking for more investment ideas?

If Danaher has you thinking more broadly about opportunities, now is a good time to widen your net and line up a few fresh prospects.

• Target dependable income by scanning for companies that may offer stronger yield profiles and resilient cash flows through the 10 dividend fortresses.
• Spot potential mispricings early by reviewing companies that combine reasonable valuations with quality fundamentals using the 46 high quality undervalued stocks.
• Strengthen your shortlist with companies that carry less financial risk and steadier profiles via the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.